Related Experiment Video
Updated: May 3, 2026
Creating Avian Forebrain Chimeras to Assess Facial Development
Published on: February 18, 2021
Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth
Richard T Williams1, Lisa M Barnhill1, Huan-Hsien Kuo2
1Department of Pediatric Hematology/Oncology, University of California San Diego, San Diego, California, United States of America.
Abstract:
The INK4A locus codes for two independent tumor suppressors, p14ARF and p16/CDKN2A, and is frequently mutated in many cancers. Here we report a novel deletion/substitution from CC to T in the shared exon 2 of p14ARF/p16 in a melanoma cell line. This mutation aligns the reading frames of p14ARF and p16 mid-transcript, producing one protein which is half p14ARF and half p16, chimera ARF (chARF), and another which is half p16 and half non-p14ARF/non-p16 amino acids, p16-Alternate Carboxyl Terminal (p16-ACT). In an effort to understand the cellular impact of this novel mutation and others like it, we expressed the two protein products in a tumor cell line and analyzed common p14ARF and p16 pathways, including the p53/p21 and CDK4/cyclin D1 pathways, as well as the influence of the two proteins on growth and the cell cycle. We report that chARF mimicked wild-type p14ARF by inducing the p53/p21 pathway, inhibiting cell growth through G2/M arrest and maintaining a certain percentage of cells in G1 during nocodazole-induced G2 arrest. chARF also demonstrated p16 activity by binding CDK4. However, rather than preventing cyclin D1 from binding CDK4, chARF stabilized this interaction through p21 which bound CDK4. p16-ACT had no p16-related function as it was unable to inhibit cyclin D1/CDK4 complex formation and was unable to arrest the cell cycle, though it did inhibit colony formation. We conclude that these novel chimeric proteins, which are very similar to predicted p16/p14ARF chimeric proteins found in other primary cancers, result in maintained p14ARF-p53-p21 signaling while p16-dependent CDK4 inhibition is lost.
Insights
A novel mutation in the INK4A locus creates chimeric proteins (chARF and p16-ACT) in melanoma. Chimera ARF maintains tumor suppressor p53/p21 signaling but loses p16-dependent cell cycle inhibition.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The INK4A locus encodes tumor suppressors p14ARF and p16/CDKN2A, frequently altered in cancers.
- Mutations in this locus can lead to novel protein products with altered functions.
Purpose of the Study:
- To investigate the cellular impact of a novel deletion/substitution mutation in the shared exon 2 of p14ARF/p16.
- To analyze the functional consequences of the resulting chimeric proteins, chARF and p16-ACT, on cancer cell pathways and growth.
Main Methods:
- A melanoma cell line with a novel CC to T mutation in INK4A exon 2 was identified.
- The chimeric proteins, chARF and p16-ACT, were expressed and analyzed.
- Key cancer pathways, including p53/p21 and CDK4/cyclin D1, were assessed.
- Cell growth, cell cycle progression, and colony formation were evaluated.
Main Results:
- Chimera ARF mimicked wild-type p14ARF, activating the p53/p21 pathway and inducing G2/M arrest.
- chARF bound CDK4 but stabilized the cyclin D1/CDK4 complex via p21, losing canonical p16 function.
- p16-ACT did not inhibit cyclin D1/CDK4 or arrest the cell cycle but reduced colony formation.
Conclusions:
- Novel chimeric proteins arising from INK4A mutations can preserve p14ARF-p53-p21 signaling.
- These mutations lead to a loss of p16-dependent CDK4 inhibition, potentially contributing to cancer progression.
- The findings are relevant to understanding similar chimeric proteins found in other primary cancers.
Related Concept Videos
02:23Abnormal Proliferation
02:37Restarting Stalled Replication Forks